A Trial of Inebilizumab in Participants With Autoimmune Hepatitis

Summary

The main objectives of this trial are to evaluate the safety and tolerability of inebilizumab in participants with autoimmune hepatitis (AIH) (Part 1) and to evaluate the efficacy of inebilizumab on AIH disease activity and glucocorticoid (GC) use in the management of AIH (Part 2).

Timeline

Start

2026-09-07

Primary completion

2031-07-30

Completion

2034-02-11

Drugs

Indications